<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476813</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1106-PR-0066</org_study_id>
    <nct_id>NCT01476813</nct_id>
  </id_info>
  <brief_title>Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess Efficacy and Safety of 3 Free Doses of Glycopyrrolate With Beclomethasone/Formoterol pMDI for the Treatment of COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      dose-finding study to assess the optimal dose of glycopyrrolate daily dose on top of BDP/FF
      in COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 4-WAY CROSS-OVER STUDY TO
      EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF GLYCOPYRROLATE WITH
      FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL (FOSTER®) IN A METERED DOSE
      INHALER FOR THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aera under curve FEV1 AUC 0-12h</measure>
    <time_frame>day 1 and 7 of treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Glyco 25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/FF (400/24 daily)+ Glyco 25µg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/FF (400/24 daily)+ Glyco 50 µg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/FF (400/24 daily)+ Glyco 100µg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP/FF 400/24</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/FF 400/24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Glyco 25</arm_group_label>
    <other_name>Foster+GLyco 25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Glyco 50</arm_group_label>
    <other_name>Foster+GLyco 50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>Glyco 100</arm_group_label>
    <other_name>Foster+GLyco 100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>comparison of different dosages of drug versus comparator</description>
    <arm_group_label>BDP/FF 400/24</arm_group_label>
    <other_name>Foster</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD over 40 years of age (30 to 60% post-bronchodilator FEV1 predictive value)

          -  Patients under Double

          -  Patients under triple therapy (for 1 Mo prior Screening)

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or
             antibiotics, hospitalization

          -  concommitant diseases impacting feasibility or safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit Ltd, Manchester University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit Ltd.</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003588-31</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z; TRIDENT study investigators. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26.</citation>
    <PMID>27109816</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

